Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
20
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Kalaris Therapeutics Inc. market cap is $27.96M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Kalaris Therapeutics Inc. 52 week high is $11.88 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Kalaris Therapeutics Inc. 52 week low is $1.25 as of November 22, 2026.
Kalaris Therapeutics Inc. stock price today is $1.28.
Kalaris Therapeutics Inc. stock price yesterday was $1.35.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Kalaris Therapeutics Inc.'s P/E ratio is -0.7.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Kalaris Therapeutics Inc. P/B ratio is 0.6428.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Kalaris Therapeutics Inc. 50-day moving average is $2.33.